LC-MS/MS Estimation Of The Anti-Cancer Agent Entrectinib Levels In Human Plasma Samples

Abstract

Entrectinib is a tyrosine kinase inhibitor; hence, it acts on several receptors. It acts as an adenosine triphosphate competitor and inhibits tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, and TRKC, and also as proto-oncogene tyrosine-protein kinase ROS1and anaplastic lymphoma kinase (ALK). TRK receptors produce cell proliferation through downstream signaling through the mitogenactivated protein kinase, phosphoinositide 3-kinase, and phospholipase C-γ. ALK produces similar signaling with the addition of downstream JAK/STAT activation. Inhibition of those pathways suppresses neoplastic cell proliferation and shifts the balance in Favour of apoptosis, resulting in shrinking of tumor volume [1-9].